Schizophrenia Linked With Common Viral Infections
A growing body of research suggests there may be associations between common viral infectious such as Epstein Barr and Toxoplasma gondii and schizophrenia.
Schizophrenia and Psychoses
SCHIZOPHRENIA AND PSYCHOSES
Featured Article
Latest News
Predictors of Violence Identified Among Individuals With Schizophrenia
Baseline injurious violence, recent violent victimization, and medication nonadherence are strong predictors of future injurious violence among individuals with schizophrenia.
Enhanced Texting Intervention Improves Medication Compliance in Schizophrenia
The LEAN program demonstrated a 27% improvement in adherence, compared with the 15%-18% range reported for other text message interventions.
Leveraging Neuroimaging for the Diagnosis of Psychiatric and Neurodegenerative Diseases
A number of psychiatric and neurodegenerative diseases are associated with abnormal imaging findings, which can help psychiatrists reach a diagnosis.
Leveraging Pharmacogenetic Testing to Improve Treatment Adherence in Mental Illness
Leveraging pharmacogenetics for selecting treatments may benefit patients with treatment-resistant schizophrenia and other psychotic disorders.
Taking Into Account Drug-Drug Interactions When Prescribing Third-Generation Antipsychotics
Psychiatrists need to take into account possible drug-drug interactions when prescribing third generation antipsychotics to their patients with schizophrenia.
Valbenazine and Tetrabenazine Show Promise in Treating Tardive Dyskinesia
Valbenazine and tetrabenazine may represent promising options for the treatment of tardive dyskinesia in patients on long-term antipsychotic medications.
Nurse-Led Telephone Intervention Beneficial for Medication Adherence in Schizophrenia
Patients with schizophrenia who participated in a telephone intervention problem-solving program were found to have higher rates of medication adherence compared with patients who received routine hospital care for schizophrenia.
Patients With Early-Phase Schizophrenia Open to Sustained-Release Medication
Researchers infer from their study’s enrollment that patients with early-phase schizophrenia are willing to try long-acting injectable antipsychotic treatment.
Abnormal Superficial White Matter Connectivity Linked to Schizophrenia, Bipolar Disorder
Generalized fractional anisotropy reductions in bundles connecting regions involved in mood regulation and motor function were seen in patients with schizophrenia and bipolar disorder.
Novel Treatment for Schizophrenia Gets FDA’s Breakthrough Therapy Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia. SEP-363856 is believed to work by activating trace amine-associated receptor 1 (TAAR1) in addition to 5-HT1A receptors; unlike other antipsychotics, this novel agent does not bind to D2 or 5-HT2A receptors. The Breakthrough Therapy designation was…
Want to read more?
Please login or register first to view this content.
Next post in Schizophrenia and Psychoses